Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime

Precision Medicine: From Science To Value

(2018) Geoffrey S. Ginsburg et al.   HEALTH AFFAIRS

1370. Cefepime/VNRX-5133 Broad-Spectrum Activity Is Maintained Against Emerging KPC- and PDC-Variants in Multidrug-Resistant K. pneumoniae and P. aeruginosa

(2018) Denis Daigle et al.   Open Forum Infectious Diseases

Characterizing Cefepime Neurotoxicity: A Systematic Review

(2017) Ayesha A Appa et al.   Open Forum Infectious Diseases

Population Pharmacokinetic Assessment and Pharmacodynamic Implications of Pediatric Cefepime Dosing for Susceptible-Dose-Dependent Organisms

(2016) Kensuke Shoji et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity

(2016) Nathaniel J. Rhodes et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Pharmacokinetics of Cefepime in Patients with Cancer and Febrile Neutropenia in the Setting of Hematologic Malignancies or Hematopoeitic Cell Transplantation

(2016) Laura Whited et al.   PHARMACOTHERAPY

Relationship between PK/PD of Cefepime and Clinical Outcome in Febrile Neutropenic Patients with Normal Renal Function

(2016) Yoshiko Yamashita et al.   YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN

Adequacy of High-Dose Cefepime Regimen in Febrile Neutropenic Patients with Hematological Malignancies

(2015) Fekade Bruck Sime et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival

(2015) Nathaniel J. Rhodes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evaluation of clinical outcomes in patients with Gram-negative bloodstream infections according to cefepime MIC

(2015) Nathaniel J. Rhodes et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current  -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?

(2014) J. A. Roberts et al.   CLINICAL INFECTIOUS DISEASES

Accurate Detection of Outliers and Subpopulations With Pmetrics, a Nonparametric and Parametric Pharmacometric Modeling and Simulation Package for R

(2012) Michael N. Neely et al.   THERAPEUTIC DRUG MONITORING

Cefepime in intensive care unit patients: Validation of a population pharmacokinetic approach and influence of covariables

(2011) B. Georges et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

High Cefepime Plasma Concentrations and Neurological Toxicity in Febrile Neutropenic Patients with Mild Impairment of Renal Function

(2010) F. Lamoth et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Performance of the Cockcroft-Gault, MDRD, and New CKD-EPI Formulas in Relation to GFR, Age, and Body Size

(2010) W. M. Michels et al.   Clinical Journal of the American Society of Nephrology

Population Modeling and Monte Carlo Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Rifampin in Lungs

(2009) S. Goutelle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Pharmacodynamics of Cefepime in Patients Infected with Pseudomonas aeruginosa

(2009) J. L. Crandon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetics of High-Dose, Prolonged-Infusion Cefepime in Adult Critically Ill Patients with Ventilator-Associated Pneumonia

(2009) A. M. Nicasio et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY